Hemorrhagic pericarditis with cardiac tamponade after percutaneous coronary intervention associated with the use of abciximab
The Korean Journal of Internal Medicine
;
: 156-160, 2008.
Article
Dans Anglais
| WPRIM
| ID: wpr-181611
ABSTRACT
Glycoprotein (GP) IIb/IIIa inhibitors, such as abciximab, are used as adjunctive therapy for percutaneous coronary intervention (PCI) in high-risk non-ST-elevation myocardial infarction (NSTEMI) and in ST-elevation myocardial infarction (STEMI), although their effects when used for STEMI are less clear. As the use of GP IIb/IIIa inhibitors becomes more widespread, determining the risks associated with them becomes more important. The major risks associated with the use of GP IIb/IIIa inhibitors are the potential for major bleeding and thrombocytopenia. This is the first reported case in Korea of hemorrhagic pericarditis resulting in cardiac tamponade associated with the use of abciximab, a commonly used GP Ilb/IIa inhibitor, following PCI.
Texte intégral:
Disponible
Indice:
WPRIM (Pacifique occidental)
Sujet Principal:
Péricardite
/
Fragments Fab d'immunoglobuline
/
Antiagrégants plaquettaires
/
Tamponnade cardiaque
/
Angioplastie coronaire par ballonnet
/
Facteurs de risque
/
Péricardiocentèse
/
Services des urgences médicales
/
Hémorragie
/
Corée
Type d'étude:
Etude d'étiologie
/
Facteurs de risque
Limites du sujet:
Adulte très âgé
/
Humains
/
Mâle
Pays comme sujet:
Asie
langue:
Anglais
Texte intégral:
The Korean Journal of Internal Medicine
Année:
2008
Type:
Article
Documents relatifs à ce sujet
MEDLINE
...
LILACS
LIS